[{"id":"3104391b-e3f1-42cd-bf6a-12a8612992d6","acronym":"CUARTET","url":"https://clinicaltrials.gov/study/NCT04601441","created_at":"2021-01-19T20:30:33.227Z","updated_at":"2024-07-02T16:36:37.659Z","phase":"Phase 4","brief_title":"Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan","source_id_and_acronym":"NCT04601441 - CUARTET","lead_sponsor":"Kindai University","biomarkers":" KRAS • BRAF • TP53 • PIK3CA • BRCA1 • BRCA2 • PTEN • IDH1 • IDH2 • CDKN2A • RB1 • ARID1A • AKT1 • RUNX1 • ASXL1 • CCND1 • PALB2 • MLH1 • KMT2D • MSH6 • CDK4 • MSH2 • RNF43 • CDK12 • CTNNB1 • ERCC1 • ERCC2 • FBXW7 • KMT2C • FANCA • RAD51B • KDM6A • MDM4 • PIK3R1 • RAD51C • CDK6 • PIK3CB • SPOP • FOXA1 • GNAS • ZFHX3 • AKT2 • CHD1 • CUL1 • ERCC5 • FANCF • FOXP1 • ERCC4 • CDKN1B • ERCC3 • FANCD2 • FANCE • FANCG • HSD3B1 • ZBTB16 • FANCC • NCOA2 • NKX3-1","pipe":"","alterations":" ","tags":["KRAS • BRAF • TP53 • PIK3CA • BRCA1 • BRCA2 • PTEN • IDH1 • IDH2 • CDKN2A • RB1 • ARID1A • AKT1 • RUNX1 • ASXL1 • CCND1 • PALB2 • MLH1 • KMT2D • MSH6 • CDK4 • MSH2 • RNF43 • CDK12 • CTNNB1 • ERCC1 • ERCC2 • FBXW7 • KMT2C • FANCA • RAD51B • KDM6A • MDM4 • PIK3R1 • RAD51C • CDK6 • PIK3CB • SPOP • FOXA1 • GNAS • ZFHX3 • AKT2 • CHD1 • CUL1 • ERCC5 • FANCF • FOXP1 • ERCC4 • CDKN1B • ERCC3 • FANCD2 • FANCE • FANCG • HSD3B1 • ZBTB16 • FANCC • NCOA2 • NKX3-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/06/2020","start_date":" 11/06/2020","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2020-12-08"},{"id":"91f25517-3648-4010-96ee-c139f5875d49","acronym":"CABA-BONE","url":"https://clinicaltrials.gov/study/NCT02512458","created_at":"2021-01-18T12:08:14.634Z","updated_at":"2024-07-02T16:36:50.251Z","phase":"Phase 2","brief_title":"Study of the Effect of Chemotherapy With Cabazitaxel on Prostate Cancer","source_id_and_acronym":"NCT02512458 - CABA-BONE","lead_sponsor":"Hellenic Cooperative Oncology Group","biomarkers":" TP53 • AR • CYP17A1 • NKX3-1 • UBE2C","pipe":" | ","alterations":" AR expression • TP53 expression","tags":["TP53 • AR • CYP17A1 • NKX3-1 • UBE2C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression • TP53 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cabazitaxel"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 10/29/2015","start_date":" 10/29/2015","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 12/27/2019","study_completion_date":" 12/27/2019","last_update_posted":"2020-02-10"},{"id":"6b8bf719-5c1e-4c86-a97f-384cf98014e4","acronym":"CHRU-WCMC","url":"https://clinicaltrials.gov/study/NCT03421015","created_at":"2021-01-18T16:52:39.017Z","updated_at":"2024-07-02T16:36:53.886Z","phase":"","brief_title":"Genetic Analysis of Prostate Cancer to Identify Predictive Markers of Disease Relapse or Metastatic Evolution","source_id_and_acronym":"NCT03421015 - CHRU-WCMC","lead_sponsor":"University Hospital, Lille","biomarkers":" TP53 • PIK3CA • PTEN • ERG • SPOP • TMPRSS2 • NKX3-1","pipe":" | ","alterations":" TP53 mutation • PIK3CA mutation • PTEN mutation • TMPRSS2-ERG fusion","tags":["TP53 • PIK3CA • PTEN • ERG • SPOP • TMPRSS2 • NKX3-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • PIK3CA mutation • PTEN mutation • TMPRSS2-ERG fusion"],"overall_status":"Unknown status","enrollment":" Enrollment 84","initiation":"Initiation: 05/01/2017","start_date":" 05/01/2017","primary_txt":" Primary completion: 07/01/2020","primary_completion_date":" 07/01/2020","study_txt":" Completion: 07/01/2020","study_completion_date":" 07/01/2020","last_update_posted":"2019-11-07"}]